Abstract
Summary
SC-16102, an azido pyrimidine derivative, was found to (a) reverse the Na retention induced by exogenous mineralocor-ticoids (aldosterone and DCA) with a further increase in K excretion in adrenalectomized rats, (b) produce a natriuresis with some additional K loss in non-DCA treated adrenalectomized rats and (c) elicit a pattern of electrolyte excretion qualitatively similar to that of hydrochlorothiazide in the intact rat. SC-16102 was found to be a non-specific antagonist to mineralocorticoids with the ability to reverse the DCA-induced decrease in the urinary Na/K ratio, the compound being at least 6.8 times the potency of spiro-nolactone and 2.6 times the activity of hydrochlorothiazide.
Get full access to this article
View all access options for this article.